MedTrace Logo

Study of Amblyomin-X in Advanced Solid Tumor

NCT03120130 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-10-14

No results posted yet for this study

Summary

Amblyomin-X is an inhibitor of Factor Xa that also acts as an apoptotic agent for tumor cells. In the case of in vitro assays, Amblyomin-X induces tumor cells to death and does not affect the viability of normal cells. When in vivo assays were performed on mice bearing tumors, treatment with Amblyomin-X caused a significant reduction in tumor mass and number of metastases.

Conditions

Interventions

BIOLOGICAL

Amblyomin-X

Intravenous drug administration, with different doses in each cohort

Sponsors & Collaborators

  • Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda ME

    collaborator INDUSTRY

  • União Química Farmacêutica Nacional S/A

    lead INDUSTRY

Principal Investigators

  • Paula F Santos · União Quimica

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2021-08-20
Completion
2022-05-22

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03120130 on ClinicalTrials.gov